πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

4,838 results for β€œSP” Clear

  1. Luminity 150 microlitres/ml gas and solvent for dispersion for injection/infusion, TEMOZOLOMIDE , LOMUSTINE

    Pari Pharma GmbH

    Newly diagnosed Glioblastoma (IDH wild-type) patients at initial radiological diagnosis eligible for tumor resection, and for the standard of care including concurrent temoradiation followed by adjuvant TMZ with or without Tumor Treating Fields*. (*Tumor Treating Fields is applicable only in participating centers in France)

    phase 2 small molecule active

    1 trial

  2. Luspatercept

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HSCT

    phase 2 small molecule active

    1 trial

  3. Luspatercept combined with low-dose thalidomide

    The First People's Hospital of Lianyungang

    Transfusion-dependent Ξ²-thalassemia Patients

    phase 2 small molecule active

    1 trial

  4. Lusutrombopag Oral Tablet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Idiopathic Thrombocytopenic Purpura

    phase 2 small molecule completed

    1 trial

  5. Lutathera 370 MBq/mL solution for infusion, ATEZOLIZUMAB, Tevimbra 100 mg concentrate for solution for infusion, CARBOPLATIN, LysaKare 25 g/25 g solution for infusion, NETSPOT, ETOPOSIDE

    Novartis Pharmaceuticals

    Extensive stage small cell lung cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  6. Lutikizumab, USP/Ph. Eur.ABBV-323, Universal Placebo (Lutikizumab, Ravagalimab)

    AbbVie Deutschland GmbH & Co. KG

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  7. Luveris

    Peking University Third Hospital

    Infertility

    phase 2 small molecule active

    1 trial

  8. Lynparza 100 mg film-coated tablets, CYCLOPHOSPHAMIDE, Lynparza 150 mg film-coated tablets, DOCETAXEL, DOXORUBICIN, CARBOPLATIN, EPIRUBICIN

    Shanghai Reinovax Biologics Co.,LTD

    Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoiceΒ© test)

    phase 2 small molecule active

    1 trial

  9. Lynparza 100 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Faslodex 250 mg solution for injection., Lynparza 150 mg film-coated tablets, Zoladex 3.6 mg Implant

    Ningbo Cancer Hospital

    ER-positive and HER2-negative metastatic or locally advanced breast cancer with either a germline or somatic BRCA mutation, or a deleterious alteration of other genes involved in homologous recombination repair (HRR) or in MSI status.

    phase 2 small molecule active

    1 trial

  10. MB-huCART19.1

    AXIM BIOTECHNOLOGIES, INC.

    B-cell precursor ALL, B-cell Non Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  11. MB07133

    The First People's Hospital of Lianyungang

    Safety Issues

    phase 2 small molecule active

    1 trial

  12. MEDI8897

    MedImmune

    Respiratory Syncytial Virus Infections

    phase 2 small molecule completed

    1 trial

  13. MERCAPTOPURINE, PREDNISONE, VINCRISTINE SULFATE, CYTARABINE, FILGRASTIM, LENOGRASTIM, CYTARABINE, IDARUBICIN HYDROCHLORIDE, FOLINIC ACID, Iclusig 15 mg film-coated tablets, METHYLPREDNISOLONE SODIUM SUCCINATE, CYCLOPHOSPHAMIDE, METHOTREXATE, METHOTREXATE, DEXAMETHASONE DISODIUM PHOSPHATE, Iclusig 15 mg film-coated tablets

    Fondazione Telethon ETS

    Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.

    phase 2 small molecule active

    1 trial

  14. MIE

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 other active

    1 trial

  15. MK-1045

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  16. ML-004 (IR)/(ER) tablet

    MapLight Therapeutics

    Autism Spectrum Disorder

    phase 2 small molecule active

    2 trials

  17. MLC901

    Hospital Authority, Hong Kong

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  18. MOGAMULIZUMAB

    Ningbo Cancer Hospital

    Cutaneous T-cell lymphoma, a category of cancers of lymphocytes (a type of white blood cells) that primarily involve the skin, Cutaneous T-cell lymphoma (Mycosis Fungoides (MF)) and SΓ©zary Syndrome (SS))

    phase 2 small molecule active

    1 trial

  19. MOVIPREP, MaaT033, MOVIPREP Orange, poudre pour solution buvable, Placebo is an inert coated capsule with no microbiota (active substance) inside. It is composed of a mix of coloring agents and partially pre-gelatinized corn starch in Hydroxypropyl methylcellulose capsule.

    Pari Pharma GmbH

    AXIAL SPONDYLOARTHRITIS

    phase 2 small molecule active

    1 trial

  20. MRG003 combined with Dalpicicilip

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  21. MRG003 combined with Pucotenlimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  22. MSC

    The Children's Hospital of Zhejiang University School of Medicine

    BPD - Bronchopulmonary Dysplasia

    phase 2 small molecule active

    1 trial

  23. MSC and PRP

    Hospital Authority, Hong Kong

    Type 1 Diabetes Mellitus

    phase 2 mab active

    1 trial

  24. MSC-NTF cells transplantation (IM)

    BRAINSTORM CELL THERAPEUTICS INC.

    Amyotrophic Lateral Sclerosis

    phase 2 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources